Veradigm (MDRX) Stock Price, News & Analysis

Company Overview

Veradigm, Inc. (NASDAQ: MDRX) is a healthcare technology company that provides a comprehensive suite of clinical, financial and analytical solutions to medical practices, health systems and life sciences organizations. The company’s offerings are designed to streamline electronic health record (EHR) workflows, optimize revenue cycle management and improve patient engagement through integrated software modules and cloud-based platforms.

Veradigm’s product portfolio includes EHR and practice management systems tailored to ambulatory and specialty care settings, as well as revenue cycle management services that encompass billing, coding and claims processing. The company also delivers data-driven analytics and real-world evidence solutions that enable healthcare providers and researchers to derive insights from large clinical data sets, inform population health strategies and support clinical trial recruitment.

Headquartered in Chicago, Illinois, Veradigm primarily serves the United States market, supporting thousands of physician practices and healthcare facilities across all 50 states. The company maintains partnerships with major health systems, specialty societies and pharmaceutical firms, extending its reach into areas such as telehealth integration, patient outreach and post-acute care coordination. Veradigm’s cloud infrastructure is designed to meet industry security standards and facilitate interoperability with third-party health information exchanges.

Veradigm traces its roots to the clinical and financial solutions division of Allscripts Healthcare Solutions, which was rebranded and spun off in 2022 to focus exclusively on data-centric healthcare services. Led by an executive team with deep expertise in health information technology, the company continues to invest in platform enhancements, machine learning capabilities and strategic alliances aimed at advancing digital health initiatives and improving care delivery outcomes.

Key Stats

• Today's Range: $4.62 to $5.25
• 50-Day Range: $4.21 to $5.05
• 52-Week Range: $3.00 to $11.80
• Volume: 8,337 shs
• Average Volume: 249,520 shs
• Market Capitalization: $503.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Veradigm Stock Analysis - MarketRank™

Veradigm scored higher than 51% of companies evaluated by MarketBeat, and ranked 183rd out of 326 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Veradigm has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Veradigm has a consensus price target of $13.00, representing about 179.6% upside from its current price of $4.65.

Amount of Analyst Coverage

Veradigm has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MDRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veradigm does not currently pay a dividend.

Dividend Growth

Veradigm does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.62

Short Interest

There is no current short interest data available for MDRX.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.95

News Sentiment

Veradigm has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Veradigm this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veradigm insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.29% of the stock of Veradigm is held by insiders.

MDRX Stock Analysis - Frequently Asked Questions

How have MDRX shares performed this year?

Veradigm's stock was trading at $9.75 on January 1st, 2025. Since then, MDRX shares have decreased by 52.3% and is now trading at $4.65.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) announced its earnings results on Thursday, November, 4th. The software maker reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm's revenue for the quarter was down 8.2% on a year-over-year basis.

Does Veradigm have any subsidiaries?

Veradigm subsidiaries include these companies: ZappRx, HealthGrid, and Practice Fusion.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veradigm investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Computer integrated systems design
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:MDRX
• CIK: 1124804
• Web: www.allscripts.com
• Phone: (800) 334-8534
• Fax: 313-322-9600
• Employees: 8,000
• Year Founded: 1986

Price Target and Rating

• Average Price Target for Veradigm: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +179.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.53 billion
• Price / Sales: 0.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 108,265,000
• Free Float: 105,175,000
• Market Cap: $503.43 million
• Optionable: No Data
• Beta: 0.71